Connect with us


Data Update 2 for 2023: A Rocky Year for Equities!

It is the nature of stocks that you have good years and bad ones, and much as we like to forget about the latter during market booms, they recur at regular…



It is the nature of stocks that you have good years and bad ones, and much as we like to forget about the latter during market booms, they recur at regular intervals, if for no other reason than to remind us that risk is not an abstraction, and that stocks don't always win, even in the long term. In 2022, we needed that reminder more than ever before, especially after markets came roaring back from the COVID drop in 2020 and 2021. While there are many events during 2022, some political and some economic, that one can point to as the reason for poor stock returns, it is undeniable that inflation was the driving force behind the market correction. In this post, I will begin by chronicling the damage done to equities during 2022, before putting the year in historical context, and then examine how developments during the year have affected expectations for the future. I will follow up by looking at the mechanics that connect stock prices to inflation, and examine why the damage from higher inflation can vary across companies and sectors. 

Stocks: The What?

We invest in equities expecting to earn more than we can make on risk free or guaranteed investments, but the risk in equities is that actual returns can deviate from expectations. In some years, those deviations work to our benefit and in others, it can hurt us, and 2022, unfortunately, fell into the latter column. In this section, I will begin with a deconstruction of stock returns in 2022 and the year's place in stock market history. I will then provide a template for estimating expected returns on equities, and examine how expected returns changed during the course of the year.

Actual Returns

Your returns on equities come in one of two forms. The first is the dividends you receive, while you hold stocks, a cash flow stream that provides a measure of stability to investors who seek it. The other, and less predictable component, is the price change, which in good years adds to the return as a price appreciation, and in bad years, often  overwhelms dividends to deliver negative returns.

The Year in Review

At the start of 2022, the S&P 500 was at 4766.18, up from 3756.07 at the start of that year. During the course of 2022, the index was staggered by political events, with Russia's invasion of Ukraine upending global economies, and by inflation, which entered the year high, and continued on that path through the course of the year. The graph below shows the S&P 500 at the end of each month, from December 31, 2021 to December 31, 2022, and the resulting monthly returns:

Aggregating over the entire year, the index declined 19.42% in 2022, and while the dividends during the course of the year rose, the dividend yield of 1.41% provided only a minor offset, resulting in total returns of -18.01% on the S&P 500 for the year:

I know that this is US-centric and large-cap oriented and I will cover returns in other geographies and across broader classes of stocks in my next few posts, but suffice to say, that in this year, there were no sectors or geographies that were spared.

And in historical context

    It is undeniable that 2022 was a bad year for stocks, but in historical context, how bad  a year was it? I maintain a database of historical returns on stocks, bonds, bills and other asset classes on my webpage, and I looked at the annual returns, by year, starting in 1928 through 2022 for US stocks. In the graph below, I look at the distribution of annual returns over those 95 years, paying special attention to the negative years:

S&P 500 officially came into existence in 1957, but we filled in earlier years using stock return data

As you can see, it is not uncommon for stocks to have negative years, but the returns in 2022 of -18.01% put them at the tail end of the historical distribution. In the table below, I look at how 2022 ranks in terms of bad years over the 1928 - 2022 time period:

In nominal terms, i.e., before taking into account inflation, 2022 ranks as the seventh worst year, over the 95-year time period, and in real terms, it moves up to being the sixth worst year, with real returns of -23.48%. No matter how you slice it, there is no denying that 2022 was the worst year for US equity investors since 2008, and the magnitude of the damage is even more staggering, if you consider it in market value terms. During the course of 2022, US equities collectively lost $11.6 trillion in market capitalization, but for balance, it is also worth noting that US equities are still holding on to a gain of $6.9 trillion on their market capitalization at the end of 2019. Given that we endured a pandemic, multiple political crises and wars in the three years since, that is almost a miracle.

Expected Returns

    Markets are driven by expectations, and while expectations for the future can be affected by what has happened in the past, they are still worth exploring. After a year of being pummeled by markets, what are investors pricing stocks to make in 2023 and beyond? And will they be disappointed or delighted by what the year delivers? Those are the questions that investors have to answer today and I will try to provide my perspective in this section.

Actual vs Expected Returns

    As you saw in the previous section, actual returns on stocks can be negative, and significantly negative, in some periods, and those negative returns can sometimes extend into decades. Those who invested in the Nikkei at its peak on December 29, 1989, have spent the decades since trying to get back to that level. The notion that stocks always win in the long term is a dangerous one, and while those pushing it claim to have the data on their side, it is worth remembering that the use of US data to make this case is statistically flawed. The US was one of the most successful of global equity markets of the twentieth century, and to use its historical record as the basis for all equity investment in the future strikes me as wrong headed.

    That said, when investors buy equities, it would be both irrational and illogical to settle for expected returns that are less than what you can earn on risk free or guaranteed investments, though behavioral finance suggests that both irrationality and illogic are persistent human traits. The premium that investors demand over and above the risk free rate is the equity risk premium, and practitioners in finance have wrestled with how best to estimate that number, since it is not easily observable (unlike the expected return on a bond which manifests as a current market interest rate). 

a. Historical Equity Risk Premium

    The conventional wisdom, at least as taught in business schools and practiced by appraisers, is that the only practice way to estimate equity risk premiums for the future is to use equity risk premiums earned in the past. Thus, historical risk premiums are viewed as the best estimates for the future, though analysts disagree not only about how far back in time they should go, whether to compare stock returns to T.Bill or T.Bond returns and even on how to compute the historical average return (arithmetic versus geometric averages). The graph and table below provide my estimates of the historical equity risk premiums in the US market:

As you can see, I arrive at premiums ranging from 4.12% to 13.08%, depending upon my estimation choices on time period, treasury rate used and averaging approach, but I don't use any of these numbers as my estimate for the future for two reasons. The first is that the use of historical risk premiums is predicated on the belief that the future will look like the past, and the world, in all its dimensions, has changed dramatically over the last few decades. The second is that even if you are comfortable with assuming mean reversion, the estimates from the past are extremely noisy (have large standard errors), with the premium from 1928 to 2022 having a standard error of 2.15%. In effect, even with that long period, the best I can offer, if you are looking for an equity risk premium for stocks over T.Bonds is a range so wide (2.34% - 10.94%, i.e., the average plus or minus two standard errors) that it is not useful

Implied Expected Returns

    There is another approach to estimating expected returns on stocks, and equity risk premiums, and it is forward-looking. It too requires estimate for inputs, but the range of error is magnitudes smaller than with historical premiums. In this approach, I draw on a technique used to compute the yield to maturity on a bond, the discount rate that makes the present value of cash flows on the bond (coupons and face value) equal to the price of the bond, and extend it to equities. To illustrate, I estimate this implied equity risk premium for the S&P 500 at the start of 2023, using the index level as the price that I pay on the index and using market estimates of earnings and dividends/buybacks on the index for the next five years and beyond. 

As with the yield to maturity for a bond, I solve for the discount rate (IRR) that makes the present value of cashflows on the index equal to the level of the index. At the start of 2023, by my calculations and with analyst estimates of earnings, I estimate an expected return of 9.82%. which when you net out the T.Bond rate that day results in an implied equity risk premium of 5.94%. There are clearly input estimates that you can take issue with, especially on earnings and cashflows. Thus, if you assume that analysts are over estimating earnings and/or that companies will return less of these earnings to investors in the form of dividends and buybacks, the estimated equity risk premium will decrease, and if you assume that growth will be stronger than forecast, the equity risk premium will rise. In this spreadsheet, you can see that making different assumptions on these fronts yields equity risk premiums ranging from 4.83% to about 6%, a much narrower range than from historical risk premiums.

In historical context

   In my first data post, I noted the increase in equity risk premiums during 2022 from 4.24% at the start of 2022 to 5.94% at the start of 2023. I posited that any debate about whether the market, as it stands now, is fairly, under or over valued is really one about whether the equity risk premium at the start of 2023 is too high (in which case, the market is under valued) or too low (in which case, it is overvalued). To answer that question, and address the question of where the expected return of 9.82% stands in historical context, I report the expected returns and equity risk premiums for the S&P 500 from 1960 to 2022:

At 5.94%, the implied equity risk premium is closer to top of the range of historical risk premiums, but the most striking feature of 2022 is that the expected return on stocks, at 9.82%, is now at its highest level since 1995. 

Stocks: The So What?

    It is worth noting that in valuation, demanding a higher expected return depresses value today, and the increase in expected returns over 2022 is therefore consistent with the decline in stock prices during the year. In fact, the drop in stock prices of 20% is mild, given the surge in expected returns during the course of the year.  There is another reading of this expected return that ties into investment and growth, where the expected return on stocks is the cost of equity that companies need to clear to make investments. In short, an average-risk project with a return on equity of 7%, which would have passed the investment test at the start of 2022, because it was greater than the cost of equity of 5.75%, prevailing at the time, would not pass muster at the start of 2023. 

    The effects of a higher equity risk premium are also not uniform across all stocks, with higher risk stocks seeing much greater rises in their costs of equity than lower risk stocks. The table below provides the cost of equity distribution across US companies at the start of 2023:

Note that, for the first time in a decade, more US firms have double digit costs of equity than single digit values, and while that may seem shocking to younger analysts, it is a return to what used to be normal in the pre-2008 market.

Stocks: The What Next?

    To close this post, I revisited my valuation of the S&P 500 on September 23, 2022, and since much of last year's changes to the risk free rate, earnings expectations and the equity risk premium had happened by then, my value of the index has not changed much. In fact, if you view the current treasury bond rate as reflective of the market consensus on future inflation and rates, and assume that analyst estimates of earning already incorporate the effects of an economic slowdown in 2023 and 2024, the index value comes in at almost the current index level:

Download spreadsheet

In sum, with analyst estimates of earnings for the next two years powering earnings expectations, and an desired equity risk premium of 5% (close to the average premium in the post-2008 time period), stocks started the new year closer to fair value than being under or over valued.

    The market consensus can be wrong, and as the last year has shown, markets can change their minds, and especially so on two variables. The first is inflation, and whether it will recede to pre-pandemic levels or stay elevated, with consequences for both interest rates, nominal earnings growth in the long term and reinvestment. The second is the economy, where talk of recession fills the air but where a whole range of outcomes is possible from no recession to a steep drop off in economic indicators. 

Download spreadsheets: Low inflation & no recession, Low inflation & steep recession, High inflation & no recession, High inflation & steep recession

As you can see, the most favorable scenario for the market is one where inflation subsides quickly to pre-pandemic levels (1-2%), bringing down the treasury bond rate, and the economy escapes a recession, leaving corporate earnings unscathed; in this scenario, the index value is 4311, about 10% higher than the current level (in January 2023). In the least favorable scenario, inflation stays high, pushing interest rates further up,  and the economy enters a steep recession, with earnings dropping 20% (10%) from analyst estimates for 2023 and 2024; in this scenario, the index value is 3212, leaving the market over valued by almost 20%. Note that I am not calling it the worst case scenario, because that depends on how high  inflation gets, with the higher the inflation, the more dire the outcomes for stocks, as well as how bad a recession is, with worse economic outcomes lowering value more.

Summing up
    One of the rituals that start the market year is for market strategists at investment banks to make their best predictions for where they see markets going over the course of the year. While this exercise has zero predictive power, and perhaps even a perverse relationship with actual returns, it does offer some insights into how much strategists are in agreement or disagreement about the year to come. At the start of 2023, here are the predictions from strategists for the year:

What should you do with these forecasts? Absolutely nothing, but the wide divergence in forecasts comes from different expectations of how the inflation/real economy story will play out. Rather than adopt one of their outlooks, or mine, you should, as an investor, find your point of view and let it drive your investment actions for the year. The first step in being a good investor is to take ownership of your investment decisions, and I hope that my framework/spreadsheet helps you on that path.

YouTube Videos

Datasets (If you have download trouble, switch browsers)

Read More

Continue Reading


Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…



To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading


Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….



Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 


About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

Read More

Continue Reading


Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.



Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 


This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading